Immunotherapy Drugs Market
Immunotherapy Drugs Market Size, Share & Trends Analysis Report, By Type (Monoclonal Antibodies, Checkpoint Inhibitors, Interferons & Interleukins, and Others), By Therapeutic Application (Cancer, Infectious Diseases, Autoimmune & Inflammatory, Other), By End-User (Hospitals, Clinics, Others), Forecast Period (2022-2028)
Immunotherapy drugs market is anticipated to grow at a CAGR of 9.0% during the forecast period. The rising prevalence of cancer, increasing demand for monoclonal antibodies and biosimilars along with increasing adoption of immunotherapy drugs over conventional treatments are some factors driving the market growth. Cancer is one of the leading causes of mortalities globally, accounting for nearly 10 million mortalities in 2020, or nearly one in six deaths. Immunotherapy is a kind of cancer treatment that boosts the body’s natural immune system to fight cancer cells. It uses the components made by the organization or in vitro in the laboratory. Different types of immunotherapy work in different mechanisms.
The rising prevalence of several infectious diseases and autoimmune diseases is supporting the demand for immunotherapy drugs. In July 2022, NovAccess Global Inc., a biomedical company developing novel immunotherapies for brain tumor patients, announced the filing of an application with the US FDA to receive Orphan Drug Designation (ODD) for TLR-AD1, vaccine immunotherapy for the treatment of aggressive brain cancers, including glioblastoma and other high-grade gliomas. Such developments are further contributing to market growth. However, side effects and stringent regulatory policies are key challenges to the growth of the global immunotherapy drugs market.
Impact of COVID-19 Pandemic on the Global Immunotherapy Drugs Market
The COVID-19 pandemic has positively impacted market growth. The growing focus of many companies on the development of immunotherapy-based drugs or vaccines for COVID-19 is positively influencing the market growth. Currently, BioNTech SE in collaboration with Pfizer Inc., conducting a phase III clinical trial to assess the safety, tolerability, and immunogenicity of BNT162b2 against COVID-19 in healthy participants.
Segmental Outlook
The global immunotherapy drugs market is segmented by type, therapeutic application and end-user. The market segmentation based on the type includes monoclonal antibodies, checkpoint inhibitors, interferons & interleukins, and others. Based on therapeutic application, the market is segmented into cancer, infectious diseases, autoimmune & inflammatory, and others. Based on end-user, the market is segmented into clinics, hospitals, and others. The hospitals' segment holds a considerable share in the global immunotherapy drugs market. The rising cancer treatment in hospitals coupled with the increasing demand for immunotherapy drugs for cancer treatment are some key factors contributing to the largest share of the hospitals' segment.
Regional Outlook
The global immunotherapy drugs market is further segmented based on geography including North America (the US and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East & Africa and Latin America). The market can be analyzed for a particular region or country level as per the requirement. North America is anticipated to exhibit considerable growth in the global immunotherapy drugs market. The rising cancer incidences and growing expenditure on R&D and clinical trials to develop immunotherapy drugs are some major factors driving the market growth in the region. The presence of key market players across the region is further contributing to the market growth.
Global Immunotherapy Drugs Market Growth, by Region 2022-2028
Asia-Pacific to Exhibit Considerable Growth in the Global Immunotherapy Drugs Market
Asia-Pacific region is anticipated to exhibit considerable growth in the global immunotherapy drugs market during the forecast period. The growing development of immunotherapy drugs across the region, growing funding for biotech research, and rising approval for clinical trials for immunotherapy drugs are key factors contributing to the growth of the regional growth. For instance, in July 2022, Sosei Group Corp., an international biopharmaceutical company and Cancer Research UK, the world’s largest private funder of cancer research signed an agreement to bring Sosei Heptares’ cancer immunotherapy drug candidate into a first-in-human trial.
Market Players Outlook
The major companies serving the global immunotherapy drugs market include F. Hoffman L-Roche Ltd., Pfizer Inc., and Merck & Co., Inc., among others. The companies are focusing on product innovation, geographical expansions, mergers and acquisitions, and finding a new market or innovation in their core competency to expand individual market share. For instance, in February 2022, the US Food and Drug Administration issued an emergency use authorization (EUA) for a new monoclonal antibody for the treatment of COVID-19 that retains activity against the omicron variant. The EUA for bebtelovimab by Eli Lilly and Co. is for the treatment of mild to moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kilograms, which is about 88 pounds) with a positive COVID-19 test, and who are at high risk for progression to severe COVID-19, including hospitalization or mortality, and for whom alternative COVID-19 treatment options approved or authorized by the FDA are not accessible or clinically appropriate.
The Report Covers
- Market value data analysis of 2021 and forecast to 2028.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global immunotherapy drugs market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
• Current Industry Analysis and Growth Potential Outlook
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Region
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Key Company Analysis
3.1.1. Overview
3.1.2. Financial Analysis
3.1.3. SWOT Analysis
3.1.4. Recent Developments
3.2. Key Strategy Analysis
4. Market Segmentation
4.1. Global Immunotherapy Drugs Market, By Type
4.1.1. Monoclonal Antibodies
4.1.2. Checkpoint Inhibitors
4.1.3. Interferons & Interleukins
4.1.4. Other
4.2. Global Immunotherapy Drugs Market, By Therapeutic Application
4.2.1. Cancer
4.2.2. Infectious Diseases
4.2.3. Autoimmune & Inflammatory
4.2.4. Other
4.3. Global Immunotherapy Drugs Market, By End-User
4.3.1. Hospitals
4.3.2. Clinics
4.3.3. Others
5. Regional Analysis
5.1. North America
5.1.1. United States
5.1.2. Canada
5.2. Europe
5.2.1. UK
5.2.2. Germany
5.2.3. Italy
5.2.4. Spain
5.2.5. France
5.2.6. Rest of Europe
5.3. Asia-Pacific
5.3.1. China
5.3.2. India
5.3.3. Japan
5.3.4. South Korea
5.3.5. Rest of Asia-Pacific
5.4. Rest of the World
6. Company Profiles
6.1. AbbVie Inc.
6.2. Amgen Inc.
6.3. AstraZeneca Plc
6.4. Bayer AG
6.5. BioNTech SE
6.6. Boehringer Ingelheim GmbH
6.7. Bristol-Myers Squibb Inc.
6.8. F. Hoffmann-La Roche Ltd.
6.9. Genmab
6.10. Gilead Sciences
6.11. GlaxoSmithKline Plc
6.12. Immatics Biotechnologies
6.13. Johnson & Johnson
6.14. Merck & Co.
6.15. NBE Therapeutics,
6.16. Novartis International AG
6.17. Pfizer Inc.
6.18. Sanofi SA
6.19. Teva Pharmaceuticals Ltd.
1. GLOBAL IMMUNOTHERAPY DRUGS MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
2. GLOBAL MONOCLONAL ANTIBODIES DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
3. GLOBAL CHECKPOINT INHIBITORS DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
4. GLOBAL INTERFERONS & INTERLEUKINS DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
5. GLOBAL OTHER IMMUNOTHERAPY DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
6. GLOBAL IMMUNOTHERAPY DRUGS MARKET RESEARCH AND ANALYSIS BY THERAPEUTIC APPLICATION, 2021-2028 ($ MILLION)
7. GLOBAL IMMUNOTHERAPY DRUGS FOR CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
8. GLOBAL IMMUNOTHERAPY DRUGS FOR INFECTIOUS DISEASES MARKET RESEARCH, AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
9. GLOBAL IMMUNOTHERAPY DRUGS FOR AUTOIMMUNE & INFLAMMATORY MARKET RESEARCH, AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
10. GLOBAL IMMUNOTHERAPY DRUGS FOR OTHER THERAPEUTIC APPLICATIONS MARKET RESEARCH, AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
11. GLOBAL IMMUNOTHERAPY DRUGS MARKET RESEARCH AND ANALYSIS BY END-USER, 2021-2028 ($ MILLION)
12. GLOBAL IMMUNOTHERAPY DRUGS IN HOSPITALS MARKET RESEARCH, AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
13. GLOBAL IMMUNOTHERAPY DRUGS IN CLINICS MARKET RESEARCH, AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
14. GLOBAL IMMUNOTHERAPY DRUGS IN OTHER END-USERS MARKET RESEARCH, AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
15. NORTH AMERICAN IMMUNOTHERAPY DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
16. NORTH AMERICAN IMMUNOTHERAPY DRUGS MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
17. NORTH AMERICAN IMMUNOTHERAPY DRUGS MARKET RESEARCH AND ANALYSIS BY THERAPEUTIC APPLICATION, 2021-2028 ($ MILLION)
18. NORTH AMERICAN IMMUNOTHERAPY DRUGS MARKET RESEARCH AND ANALYSIS BY END-USER, 2021-2028 ($ MILLION)
19. EUROPEAN IMMUNOTHERAPY DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
20. EUROPEAN IMMUNOTHERAPY DRUGS MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
21. EUROPEAN IMMUNOTHERAPY DRUGS MARKET RESEARCH AND ANALYSIS BY THERAPEUTIC APPLICATION, 2021-2028 ($ MILLION)
22. EUROPEAN IMMUNOTHERAPY DRUGS MARKET RESEARCH AND ANALYSIS BY END-USER, 2021-2028 ($ MILLION)
23. ASIA-PACIFIC IMMUNOTHERAPY DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
24. ASIA-PACIFIC IMMUNOTHERAPY DRUGS MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
25. ASIA-PACIFIC IMMUNOTHERAPY DRUGS MARKET RESEARCH AND ANALYSIS BY THERAPEUTIC APPLICATION, 2021-2028 ($ MILLION)
26. ASIA-PACIFIC IMMUNOTHERAPY DRUGS MARKET RESEARCH AND ANALYSIS BY END-USER, 2021-2028 ($ MILLION)
27. REST OF THE WORLD IMMUNOTHERAPY DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
28. REST OF THE WORLD IMMUNOTHERAPY DRUGS MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
29. REST OF THE WORLD IMMUNOTHERAPY DRUGS MARKET RESEARCH AND ANALYSIS BY THERAPEUTIC APPLICATION, 2021-2028 ($ MILLION)
30. REST OF THE WORLD IMMUNOTHERAPY DRUGS MARKET RESEARCH AND ANALYSIS BY END-USER, 2021-2028 ($ MILLION)
1. GLOBAL IMMUNOTHERAPY DRUGS MARKET SHARE BY TYPE, 2021 VS 2028 (%)
2. GLOBAL IMMUNOTHERAPY DRUGS MARKET SHARE BY THERAPEUTIC APPLICATION, 2021 VS 2028 (%)
3. GLOBAL IMMUNOTHERAPY DRUGS MARKET SHARE BY END-USER, 2021 VS 2028 (%)
4. GLOBAL IMMUNOTHERAPY DRUGS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
5. GLOBAL MONOCLONAL ANTIBODIES IMMUNOTHERAPY DRUGS MARKET SHARE BY REGION, 2021 VS 2028 (%)
6. GLOBAL CHECKPOINT INHIBITORS IMMUNOTHERAPY DRUGS MARKET SHARE BY REGION, 2021 VS 2028 (%)
7. GLOBAL INTERFERONS & INTERLEUKINS IMMUNOTHERAPY DRUGS MARKET SHARE BY REGION, 2021 VS 2028 (%)
8. GLOBAL OTHER IMMUNOTHERAPY DRUGS MARKET SHARE BY REGION, 2021 VS 2028 (%)
9. GLOBAL IMMUNOTHERAPY DRUGS FOR CANCER MARKET SHARE BY REGION, 2021 VS 2028 (%)
10. GLOBAL IMMUNOTHERAPY DRUGS FOR INFECTIOUS DISEASES MARKET SHARE BY REGION, 2021 VS 2028 (%)
11. GLOBAL IMMUNOTHERAPY DRUGS FOR AUTOIMMUNE & INFLAMMATORY DISEASES MARKET SHARE BY REGION, 2021 VS 2028 (%)
12. GLOBAL IMMUNOTHERAPY DRUGS FOR OTHER THERAPEUTIC APPLICATIONS MARKET SHARE BY REGION, 2021 VS 2028 (%)
13. GLOBAL IMMUNOTHERAPY DRUGS IN HOSPITALS MARKET SHARE BY REGION, 2021 VS 2028 (%)
14. GLOBAL IMMUNOTHERAPY DRUGS IN CLINICS MARKET SHARE BY REGION, 2021 VS 2028 (%)
15. GLOBAL IMMUNOTHERAPY DRUGS IN OTHER END-USERS MARKET SHARE BY REGION, 2021 VS 2028 (%)
16. US IMMUNOTHERAPY DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
17. CANADA IMMUNOTHERAPY DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
18. UK IMMUNOTHERAPY DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
19. FRANCE IMMUNOTHERAPY DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
20. GERMANY IMMUNOTHERAPY DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
21. ITALY IMMUNOTHERAPY DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
22. SPAIN IMMUNOTHERAPY DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
23. REST OF EUROPE IMMUNOTHERAPY DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
24. INDIA IMMUNOTHERAPY DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
25. CHINA IMMUNOTHERAPY DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
26. JAPAN IMMUNOTHERAPY DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
27. SOUTH KOREA IMMUNOTHERAPY DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
28. REST OF ASIA-PACIFIC IMMUNOTHERAPY DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
29. REST OF THE WORLD IMMUNOTHERAPY DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
